|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 13770 Noel Road |
Address2 | Suite 801889 |
City | Dallas |
State | TX |
Zip Code | 75280 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401103626-12
|
||||||||
|
6. House ID# 428950001
|
TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Molly Guthrie |
Date | 10/21/2021 2:48:43 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY2022 Labor, HHS, and Education appropriations bill related to funding for biomedical research, NBCCEDP, social determinants of health programs, and related cancer services and report language related to metastatic breast cancer
FY2022 Defense appropriations bill related to funding and issues pertaining to the congressionally-directed medical research program, especially those relating to breast cancer
H.R. 869/S. 289 - Research Investment to Spark the Economy Act of 2021; bill to authorize federal agencies to provide support for research regarding COVID-19 or research disrupted by the COVID-19 pandemic
H.R. 5376 - Build Back Better Act, efforts to influence policies included in the Build Back Better Act
Implementation of the American Rescue Plan
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
H.R. 4612/S. 2412 - Protecting Access to Lifesaving Screenings Act of 2021; a bill to make a series of changes relating to health insurance coverage of screening mammography
S. 1067 - Access to Breast Cancer Diagnosis Act; bill to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging
H.R. 2163/S. 464 - Safe Step Act; bill to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes
H.R. 4385 - Cancer Drug Parity Act; bill to require health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications.
Implementation of the No Surprises Act including comments related to PRA Listings for the Implementation of the No Surprises Act (CMS-10780 & CMS-10779)
Implementation of the Affordable Care Act
Public and private insurance adjustments and other policy changes due to the COVID-19 emergency, including those impacting the immunocompromised populations
No Junk Plans Act; bill to overturn previous administration rule expanding non-comprehensive health insurance plans that dont have to provide healthcare coverage for people with pre-existing conditions
Policies related to co-pay assistance programs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Treasury - Dept of, Labor - Dept of (DOL), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 469 - Comprehensive Breast Reconstruction Act of 2021; bill provides for Medicare, Medicaid, and private health insurance coverage of certain tattooing services in connection with post-mastectomy breast reconstruction, and aligns the scope of Medicare and Medicaid coverage of such breast reconstruction with that of private health insurance.
H.R. 1946/S. 1873 - Multi-Cancer Early Detections Screening and Coverage Act; bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening test
H.R. 3183/S. 1312 - Metastatic Breast Cancer Access to Care Act; bill to exempt individuals with metastatic breast cancer from certain waiting periods for disability insurance benefits under the Old-Age, Survivors, and Disability Insurance program and related Medicare coverage
H.R. 2903/S. 1512 - CONNECT for Health Act; a bill to expand the use of telehealth and remote patient monitoring services in Medicare
H.R. 3087/S. 2051 - Breast Cancer Patient Equity Act; a bill to provide for Medicare coverage of custom fabricated breast prostheses
H.R. 3517/S. 1943 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act; a bill to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement
H.R. 3630/S. 1315 - Lymphedema Treatment Act; bill to include certain lymphedema compression treatment items as covered durable medical equipment under Medicare following the surgical removal of the breast (i.e., a mastectomy), including replacements of such prostheses
H.R. 4110 - Reducing Hereditary Cancer Act of 2021; a bill to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation in a blood relative or a personal or ancestral history suspicious for hereditary cancer, and to provide coverage of certain cancer screenings or preventive surgeries that would reduce the risk for individuals with a germline (inherited) mutation associated with a high risk of developing a preventable cancer
H.R. 4414 - Cancer Care Planning and Communications Act of 2021; a bill to provide for Medicare coverage and payment of cancer care planning and coordination services for individuals who are diagnosed with or treated for cancer, including the development of treatment plans, follow-up care, and any necessary revisions
H.R. 4612/S. 2412 - Protecting Access to Lifesaving Screenings Act of 2021; a bill to make a series of changes relating to health insurance coverage of screening mammography including preserving Medicare coverage for screening mammography, without a requirement for coinsurance, and expands the definition of screening mammography to include any digital modality of such a procedure
S. 2327 - Seniors Prescription Drug Relief Act; a bill to amend title XVIII of the Social Security Act to provide for a Medicare part D modernization redesign and to establish a monthly out-of-pocket cost sharing maximum for enrollees who incur a significant portion of costs towards the annual out-of-pocket threshold under Medicare part D
Medicare coverage policy for drugs and drug pricing
Medicare coverage policy for breast cancer treatments and services
Proposed waivers under Sections 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid
Policies related to funding, state incentives, and federal efforts for for Medicaid expansion
Coverage for telemedicine in Medicare
Comments related to the design of an Advanced Projects Research Agency for Health
Comments related to CY 2022 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies (CMS-1751-P)
Comments Related to Notice on Benefit and Payment Parameters; Patient Protection and Affordable Care Act; Updating Payment Parameters, Section 1332 Waiver Implementing Regulations, and Improving Health Insurance Markets for 2022 and Beyond Proposed Rule
Comments to Centers for Medicare and Medicaid Services on Patient Protection and Affordable Care Act; Updating Payment Parameters, Section 1332 Waiver Implementing Regulations, and Improving Health Insurance Markets for 2022 and Beyond Proposed Rule
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), White House Office, Treasury - Dept of, Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
FY 2022 Funding and issues pertaining to the congressionally-directed medical research program, especially those relating to breast cancer
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 379/S. 104 - Improving Social Determinants of Health Act; bill to require the Centers for Disease Control and Prevention (CDC) to establish a program to improve health outcomes and reduce health inequities by, for example, coordinating activities across the CDC. As part of the program, the CDC must award grants to eligible organizations to build capacity to address social determinants of health.
H.R. 469 - Comprehensive Breast Reconstruction Act of 2021; bill provides for Medicare, Medicaid, and private health insurance coverage of certain tattooing services in connection with post-mastectomy breast reconstruction, and aligns the scope of Medicare and Medicaid coverage of such breast reconstruction with that of private health insurance.
Efforts to introduce a comprehensive healthcare and biomedical research bill nicknamed Cures 2.0
Comments to Food and Drug Administration on Core Patient-Reported Outcomes in Cancer Clinical Trials: Draft Guidance for Industry (Docket No. FDA-2020-D-2303)
Comments to Department of Health and Human Services on an RFI Regarding Reporting on Pharmacy Benefits and Prescription Drug Costs, File Code CMS-9905-NC
Comments to Office of Management and Budget on health equity
Comments related to the design of an Advanced Projects Research Agency for Health
Policies related to telehealth
Policies related to COVID-19 vaccination distribution
Policies to increase clinical trial diversity and access for underrepresented populations
Policies related to Paid Family and Medical leave
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Disease Control & Prevention (CDC), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Molly |
Guthrie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |